Largest mRNA Vaccine Manufacturing Sites in Europe Launches

BioNTech SE announced on March 26, 2021, that the European Medicines Agency (EMA) approved the manufacturing of the Comirnaty COVID-19 vaccine drug product at the facility in Marburg, Germany.

The approvals make BioNTech’s Marburg manufacturing site one of the largest mRNA vaccine manufacturing sites in Europe as well as worldwide with an annual production capacity of up to one billion doses of our COVID-19 vaccine, once fully operational.

Furthermore, because of optimized operational efficiencies initiated in 2020, BioNTech has been able to increase the expected annual manufacturing capacity by 250 million doses.

'Together with our partner Pfizer, we are working continuously on multiple initiatives to respond to global demand,' stated the BioNTech press statement.

The Pfizer-BioNTech COVID-19 vaccine, which is known globally as Comirinaty, is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the European Union, and the holder of emergency use authorizations or equivalent in the United States, United Kingdom, Canada, and other countries in advance of a planned application for full marketing authorizations in these countries.